UCB announces positive new products results | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

UCB announces positive new products results

pdf english pdf french pdf nederlands

December 2nd, 2004 - UCB, a leading biopharmaceutical company, informed on three new positive developments in its Research and Development pipeline during an analysts and investors meeting hosted today.

In neurology:

• Brivaracetam (ucb 34714), a high-affinity SV2A ligand targeting neurological diseases including epilepsy, has been evaluated in a first Phase II study including patients with photosensitive epilepsy. These results will be presented at the American Epilepsy Society meeting on December 6th. The outcome of this study shows that brivaracetam provided a more potent and complete seizure suppression in these patients than shown previously in studies with Keppra, UCB's marketed anti-epileptic drug in Europe and US. This confirms the potential and broad anti-epileptic potential of the family of SV2A ligands.

• Seletracetam (ucb 44212), another high-affinity SV2A ligand has completed its first Phase I study in healthy volunteers demonstrating a high tolerability and optimal PK profile. Phase II studies in epilepsy patients are planned and will be initiated early next year.

In inflammation:

• CDP323, an oral a4-integrin inhibitor, has successfully completed a second Phase I multiple-dose study in healthy volunteers. Good plasma exposure and potent and prolonged inhibition of ligand binding to a4-integrins in an vitro whole blood assay were demonstrated. This confirms CDP323's anti-inflammatory potential in diseases such as multiple sclerosis.

The documents from today's web cast Business Review Meeting are accessible using the following web address: http://ir.ucb-group.com

Stay up-to-date on the latest news and information from UCB